title: [Chemotherapy of cysticercosis. Review about its pharmacokinetics and toxicology].
abstract: Neurocysticercosis (NCC) is the most common parasitic infection of the central nervous system. Praziquantel and albendazole are the two cestocide drugs currently used for the treatment of NCC. The present article reviews the studies on the pharmacokinetics of these compounds, both in animals and humans, that have led to more accurate, precise and short treatment schedules for NCC. Toxicological data indicate that both praziquantel and albendazole do not have severe secondary effects in the short term, however, there is still not sufficient information about their long term effects on human health, mainly with respect to albendazole, for which few studies on its effects on human cells are available. These two drugs constitute an effective treatment not only for NCC but also for several helminthiosis. To keep this advantageuos situation, health care professionals should be aware of the necessity of a more rational use of both anthelminthics, since the potentially adverse long term effects could be related to time and dose of exposure as well as to individual susceptibility. In addition, there is always the possibility that the misuse of these compounds could give rise to resistant species, that may represent a significant problem for public health in countries where parasitic diseases are endemic.
authors.affiliation: Instituto de Investigaciones Biomédicas, UNAM, Instituto Nacional de Cancerología, SSA, México, D.F. México.
authors.forename: L A
authors.initials: LA
authors.lastname: Herrera
authors.forename: L
authors.initials: L
authors.lastname: Benítez-Bribiesca
authors.forename: J
authors.initials: J
authors.lastname: Sotelo
authors.forename: P
authors.initials: P
authors.lastname: Ostrosky-Wegman
mesh_terms: D015766:Albendazole / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000871:Anthelmintics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D020019:Neurocysticercosis / Q000188:drug therapy* / Q000378:metabolism; D011223:Praziquantel / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000871:Anthelmintics; D011223:Praziquantel; D015766:Albendazole